| Document |
Document Title |
|
WO/2012/011106 |
The present invention provides an improved process for the preparation of 17-desoxy corticosteroid derivatives in a single chemical step by reacting the 17-hydroxy starting material with an excess of Trimethylsilyl Iodide. The present in...
|
|
WO/2010/139411 |
The invention relates to 17ß-alkyl-17α-oxy-estratrienes of formula (I), methods for producing the same, the use of the 17ß-alkyl-17α-oxy-estratrienes for producing medicaments, and pharmaceutical preparations containing said compounds.
|
|
WO/2010/136940 |
This invention relates to novel glucocorticoid receptor agonists of formula (I) and to processes and intermediates for their preparation. The present invention also relates to pharmaceutical compositions containing these compounds, to th...
|
|
WO/2010/071772 |
The present invention relates to methods for synthesizing preferred membrane-binding elements, preferably cholesterylamine derivatives, including 3-amino-5-cholestene (3-cholesterylamine) and related 3-halides through i-steroid and retro...
|
|
WO/2009/108388 |
Provided herein are steroidal compounds that are androsta-5,7-dienes or a pregna-5,7-dienes and ultraviolet B (UVB) conversion products thereof which includes pharmaceutical compositions of the steroidal compounds. Also provided is a met...
|
|
WO/2009/108388 |
Provided herein are steroidal compounds that are androsta-5,7-dienes or a pregna-5,7-dienes and ultraviolet B (UVB) conversion products thereof which includes pharmaceutical compositions of the steroidal compounds. Also provided is a met...
|
|
WO/2009/108388 |
Provided herein are steroidal compounds that are androsta-5,7-dienes or a pregna-5,7-dienes and ultraviolet B (UVB) conversion products thereof which includes pharmaceutical compositions of the steroidal compounds. Also provided is a met...
|
|
WO/2008/133387 |
The present invention relates to a novel acyclic triterpenoid compound and a pharmaceutical composition comprising an Alpinia katsumadai extract or acyclic triterpenoid compound isolated therefrom. The Alpinia katsumadai extract or acycl...
|
|
WO/2007/147713 |
New aminoalkoxyimino derivatives at position 3 of substituted B- homoandrostanes and B-heteroandrostanes, processes for their preparation, and to pharmaceutical compositions containing them for the treatment of cardiovascular disorders, ...
|
|
WO/2007/099548 |
11 β-hydroxyandrosta-4-ene-3-one, compound of formula (I), and physiologically acceptable salt thereof; wherein R4 represents moiety selected from a group consisting of (A), (B) and (C), with a proviso that when R4 represents moiety (C)...
|
|
WO/2007/099548 |
11 β-hydroxyandrosta-4-ene-3-one, compound of formula (I), and physiologically acceptable salt thereof; wherein R4 represents moiety selected from a group consisting of (A), (B) and (C), with a proviso that when R4 represents moiety (C)...
|
|
WO/2007/057152 |
The present invention is directed to compounds of formula (I) wherein R1 represents C4-C7 branched chain alkyl, C3-C8 cycloalkyl optionally substituted by one or more groups independently selected from C1-C3 alkyl and methoxy, C4-C6 cycl...
|
|
WO/2006/072600 |
The present invention is directed to compounds of formula (I): wherein R1 represents a 1,1-dimethylethyl group or a 1,1-dimethylpropyl group and physiologically acceptable solvates thereof, physiologically functional derivatives thereof,...
|
|
WO/2006/072599 |
The present invention is directed to compounds of formula (I): wherein R1 represents C4-C7 branched alkyl group, a bicycloalkyl group, or a C5-C6 cycloalkyl which optionally may be substituted with a C1-C4 alkyl group; R2 represents hydr...
|
|
WO/2006/032885 |
The present invention provides a compound comprising a steroidal ring system and an optional group R1 selected from any one of -OH, a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide gr...
|
|
WO/2005/077968 |
The present invention relates to novel compounds which are 7alpha-substituted 17-alkylene-16 alpha-hydroxy steroidal estrogens (see formula I). This invention specifically relates to estrogen derivatives which contain 7 alpha -substituen...
|
|
WO/2005/077968 |
The present invention relates to novel compounds which are 7alpha-substituted 17-alkylene-16 alpha-hydroxy steroidal estrogens (see formula I). This invention specifically relates to estrogen derivatives which contain 7 alpha -substituen...
|
|
WO/2005/030221 |
A drug exhibiting an excellent therapeutic efficacy for ageing macular degeneration. In particular, a therapeutic agent for ageing macular degeneration characterized in that a progesterone derivative of the general formula: (1) (wherein ...
|
|
WO/2005/030120 |
Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering compounds of the general formula (I) wherein the variables are defined in the specification.
|
|
WO/2005/005451 |
A compound of formula (I): (I) wherein X represents O or S; R1 represents C1-6 alkyl, C3-8 cycloalkyl, C3-8 cycloalkylmethyl or C3-8 cycloalkenyl any of which optionally may be substituted by one or more methyl groups or halogen atoms or...
|
|
WO/2005/005452 |
A compound of formula (I): or a physiologically acceptable solvate thereof.
|
|
WO/2004/087731 |
A method for the conversion of steroidal 17β-carboxylic acids to c carbothioic acid and esters thereof such as fluticasone propionate.
|
|
WO/2004/039827 |
A compound of formula (I): whereinR1 represents C1-6 alkyl or C1-6 haloalkyl;X represents O or S;R2 represents C3-8 cycloalkyl which optionally may be substituted by one or more groups selected from C1-6 alkyl, oxo, or halogen n is an in...
|
|
WO/2004/011663 |
Disclosed is a new synthetic pathway for the production of precursors for the production of compounds having general formula (8,10,12). During said synthesis, compounds of general formal (4,B) are produced in a microbiological reaction. ...
|
|
WO/2004/009527 |
The subject invention provides novel HMG-CoA-reductase inhibitors. In a preferred embodiment, the HMG-CoA reductase inhibitors of the subject invention can be deactivated to a primary inactive metabolite by hydrolytic enzymes. Compounds ...
|
|
WO/2004/001369 |
The present invention provides a convenient process for the preparation of S-fluoromethyl 6a, 9a-difluoro-11b-hydroxy-16a-methyl-17a-propionyloxy-3-oxoand
rosta-1, 4-diene-17b-carbothioate, a compound of formula (1), comprising(a) treati...
|
|
WO/2003/082896 |
The process for the preparation of 6&agr -fluoro steroids, comprising the reaction of the corresponding 6β-fluoro steroids, or of 6&agr /6β isomeric mixtures with an organic base having a diazo iminic group, in a suitably selected orga...
|
|
WO/2003/072592 |
A compound of formula (I): wherein R1 represents C1−6 alkyl or C1−6 haloalkyl&semi R2 represents C3−8 cycloalkyl or C3−8 cycloalkenyl either of which may be optionally substituted by one or more groups selected from C1−6 alkyl,...
|
|
WO/2003/066656 |
There is provided a crystalline complex comprising a compound of formula (I) in which the crystal lattice is stabilised by the presence of a guest molecule, characterised in that the crystalline complex is of space group P212121 having u...
|
|
WO/2003/066036 |
According to one aspect of the invention, there is provided a pharmaceutical formulation for administration by inhalation comprising a compound of formula (I), or a solvate thereof, together with a long−acting β2−adrenoreceptor agon...
|
|
WO/2003/064445 |
A compound of formula (I): wherein R1 represents C1-6 alkyl or C1-6 haloalkyl; R2 represents a 5 membered heterocyclic aromatic ring containing 1-3 heteroatoms selected from O, N and S optionally substituted with one or more methyl group...
|
|
WO/2003/051903 |
A compound represented by the general formula (I): (I) (wherein R1 represents lower alkyl&semi X represents oxygen or methylene&semi m is an integer of 1 to 10&semi and n is an integer of 0 to 5) or a salt or ester thereof&semi a medicin...
|
|
WO/2003/047329 |
A method for producing a 6a-fluorinated corticosteroid or derivative thereof by reacting a17-hydroxy-21-ester epoxide of Formula (II) with a stereoselective fluorinating agent to stereoselectively form a 21-ester-17-hydroxy 6a-fluorinate...
|
|
WO/2003/029268 |
Compounds of structural formula as herein defined are disclosed as useful in a method for modulating the androgen receptor in a tissue selective manner in a patient in need of such modulation, as well as in a method of activating the fun...
|
|
WO/2003/024943 |
The subject invention provides pharmaceutical compounds useful in the treatment of Type II diabetes. These compounds are advantageous because they are readily metabolized by the metabolic drug detoxification systems. Particularly, thiazo...
|
|
WO/2002/100878 |
A process for preparing flumethasone (6a,9a-diffluoro-11$g(b),17a,21-trihydroxy-16a-methyl-pregna
-1,4-diene-3,20-dione), fulmethasone 21-acetate or its 17-carboxyl androsten analogue which process comprises reacting a compound of formul...
|
|
WO/2002/089814 |
17-Methylene-androstan-3α-ol analogs are useful as corticotropin releasing hormone (CRH) inhibitors, and especially as anti-depressants, when administered to the vomeronasal organ. An improved synthesis of 17-methyleneandrost-4-en-3α-o...
|
|
WO/2002/072108 |
The invention relates to the use of corticosteroids and fluitcasone propionate in particular for the treatment of diseases which may be ameliorated by enhancement of epithelial/matrix adhesion.
|
|
WO/2002/042319 |
Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering derivatives of 2-methoxyestradiol of the general formula (I), wherein the variables are defined in the specification.
|
|
WO/2002/036606 |
This invention is directed to a method for treating an inflammatory condition, treating haematological and other malignancies, causing immunosuppression, or preventing or treating transplant rejection in man or other animals which compri...
|
|
WO/2002/036106 |
The invention relates to novel medicament compositions based on anticholinergics and corticosteroids, a method for the production thereof and the use thereof for treating respiratory conditions.
|
|
WO/2002/014343 |
The present invention relates to a novel use of bufadienolide derivatives, as such or in the form of pharmaceutical compositions, for immunomodulation, especially for immunosuppression, for antiinflammatory and/or for antitumor action, a...
|
|
WO/2002/008243 |
The present invention relates inter alia to a novel oxidation process for the synthesis of a known intermediate, useful in the preparation of anti-inflammatory steroids, the known intermediate being of formula (I).
|
|
WO/2002/000679 |
Compounds of formula (I), where R is a monovalent cyclic organic group having from 3 to 15 atoms in the ring system, useful as pharmaceuticals.
|
|
WO/2001/081328 |
The subject invention provides pharmaceutical compounds useful in the treatment of Type II diabetes. These compounds are advantageous because they are readily metabolized by the metabolic drug detoxification systems. Particularly, thiazo...
|
|
WO/2001/066562 |
Steroid derivatives from which various estran derivatives (estran-3-O-sulfamate derivatives serving as an inhibitor of estrogen sulfatase producing estrogen which is a causative factor of estrogen-dependent mammary cancer, mammalian ster...
|
|
WO/2001/040253 |
The invention concerns a 3-methylene steroid derivative having general formula (1) wherein R?1¿ is H or together with R?3¿ forms a $g(b)-epoxide or R?1¿ is absent if there is a 5-10 or 4-5 double bond; R?2¿ is (C¿1?-C¿5?)alkyl or C...
|
|
WO/2001/032680 |
The invention relates to novel 18-norsteroids (gonatrienes) of general formula (I), wherein R?1¿, R?2¿, R?3¿, R?6¿, R?7¿, R?8¿, R?9¿, R?11¿, R?11"¿, R?14¿, R?15¿, R?15"¿, R?16¿, R?17¿ and R?17"¿ have the meaning cited in t...
|
|
WO/2001/027133 |
The process of the present invention transforms a steroidal ketone of formula (III) to androst-4-en-17$g(b)-carboxylic acid (IV) by reaction with K¿2?SO¿5?•KHSO¿4?•K¿2?SO¿4?.
|
|
WO/2001/016601 |
Disclosed is a method for identifying a subunit specific modulator of the N-methyl-D-aspartate (NMDA) receptor. The method involves providing a plurality of NMDA receptors which differ in their subunit identity. The receptors are contact...
|
